Analysis of Revenues
Paying user area
Try for free
Becton, Dickinson & Co. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Return on Equity (ROE) since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Price to Operating Profit (P/OP) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Becton, Dickinson & Co. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
Becton, Dickinson & Co., income statement, revenues
US$ in millions
| 12 months ended: | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical | |||||||||||||
| Life Sciences | |||||||||||||
| Interventional | |||||||||||||
| Revenues |
Based on: 10-K (reporting date: 2021-09-30), 10-K (reporting date: 2020-09-30), 10-K (reporting date: 2019-09-30), 10-K (reporting date: 2018-09-30), 10-K (reporting date: 2017-09-30), 10-K (reporting date: 2016-09-30).
- Overall Revenue Trend
- Revenues have shown a generally positive trend over the analyzed period. Starting at $12,483 million in 2016, revenues decreased slightly in 2017 to $12,093 million, followed by a significant increase in 2018 to $15,983 million. This upward trajectory continued into 2019, reaching $17,290 million. There was a slight dip in 2020 to $17,117 million, after which revenues rose sharply again in 2021 to $20,248 million.
- Medical Segment
- The Medical segment exhibited some fluctuations but maintained a relatively stable revenue base. It started at $7,965 million in 2016, then declined to $7,419 million in 2017. After this dip, revenues increased to $8,616 million in 2018 and $9,064 million in 2019. There was a decrease in 2020 to $8,680 million, but the segment recovered strongly in 2021 to $9,479 million.
- Life Sciences Segment
- Life Sciences experienced a steady upward trend, with comparatively moderate growth until 2020, followed by a pronounced surge in 2021. Starting from $3,829 million in 2016, revenues increased gradually over the years: $3,988 million in 2017, $4,330 million in 2018, and a slight dip to $4,300 million in 2019. The segment improved to $4,675 million in 2020 and then exhibited a substantial jump to $6,530 million in 2021, which represents the highest growth rate among all segments.
- Interventional Segment
- The Interventional segment showed the most dynamic changes. It began with revenues of $689 million in 2016 and remained stable in 2017 at $686 million. However, in 2018, revenues surged dramatically to $3,037 million, continuing to climb to $3,926 million in 2019. A slight decline to $3,762 million occurred in 2020, followed by a recovery to $4,239 million in 2021. This segment's rapid growth largely contributes to the overall revenue increase during the period.
- Segment Contribution and Insights
- The Medical segment, although stable, shows moderate fluctuations impacting total revenue trends. Life Sciences' significant growth in 2021 suggests increased demand or successful strategic initiatives in this area. The Interventional segment's sharp rise since 2018 reflects a likely expansion or innovation, positioning it as a major growth driver. The slight revenue declines in 2020 across segments may indicate external pressures or market challenges, with subsequent recovery in 2021 highlighting resilience and positive momentum overall.